Literature DB >> 3099070

Neuropathological and clinical correlations in Hurler disease.

R W Watts, E Spellacy, J H Adams.   

Abstract

We report studies on two patients (1 and 2) with Hurler disease. They both had all of the non-neurological features of Hurler disease to a similar and extreme degree and similar signs of brain damage on computed tomography. However, intellectual function was unusually well-preserved in patient 1, but seriously and typically impaired in patient 2. The reason for this discrepancy has been investigated by reference to the neuropathological findings, the results of alpha-L-iduronidase assays using different substrates and comparisons to other cases (patients 3 and 4). We suggest that patient 1 is an unusual variant of the disease who may have had a very low residual alpha-L-iduronidase activity in neuronal cells only, and that this could not be demonstrated by either enzyme assays on whole brain using the 4-methylumbelliferyliduronide substrate (Crow et al., 1983) or in studies on fibroblast lysates using a radioactive disaccharide substrate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3099070     DOI: 10.1007/bf01799658

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

1.  A newly recognized forme fruste of Hurler's disease (gargoylism).

Authors:  H G SCHEIE; G W HAMBRICK; L A BARNESS
Journal:  Am J Ophthalmol       Date:  1962-05       Impact factor: 5.258

2.  Biochemical discrimination of Hurler and Scheie syndromes.

Authors:  J J Hopwood; V Muller
Journal:  Clin Sci (Lond)       Date:  1979-09       Impact factor: 6.124

3.  Computed tomography studies on patients with mucopolysaccharidoses.

Authors:  R W Watts; E Spellacy; B E Kendall; G du Boulay; D A Gibbs
Journal:  Neuroradiology       Date:  1981-02       Impact factor: 2.804

4.  alpha-L-iduronidase deficiency and possible Hurler-Scheie genetic compound. Clinical, pathologic, and biochemical findings.

Authors:  P R Winters; M J Harrod; S A Molenich-Heetred; J Kirkpatrick; R N Rosenberg
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

5.  Mucopolysaccharidosis type V. (Scheie syndrome). A postmortem study by multidisciplinary techniques with emphasis on the brain.

Authors:  A S Dekaban; G Constantopoulos; M M Herman; J K Steusing
Journal:  Arch Pathol Lab Med       Date:  1976-05       Impact factor: 5.534

6.  Glaucoma in a case of Hurler disease.

Authors:  E Spellacy; J L Bankes; J Crow; R Dourmashkin; D Shah; R W Watts
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

7.  Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain.

Authors:  A S Dekaban; G Constantopoulos
Journal:  Acta Neuropathol       Date:  1977-07-15       Impact factor: 17.088

8.  Postmortem findings in the Hurler-Scheie syndrome (mucopolysaccharidosis I-H/S).

Authors:  E R Wassman; K Johnson; L J Shapiro; H Itabashi; D L Rimoin
Journal:  Birth Defects Orig Artic Ser       Date:  1982

9.  Biochemical and histopathological studies on patients with mucopolysaccharidoses, two of whom had been treated by fibroblast transplantation.

Authors:  J Crow; D A Gibbs; W Cozens; E Spellacy; R W Watts
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

10.  Histopathological studies of the temporal bones in Hurler's disease [mucopolysaccharidosis (MPS) IH].

Authors:  I Friedmann; E Spellacy; J Crow; R W Watts
Journal:  J Laryngol Otol       Date:  1985-01       Impact factor: 1.469

View more
  2 in total

1.  An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life.

Authors:  Sandra D K Kingma; Eveline J Langereis; Clasine M de Klerk; Lida Zoetekouw; Tom Wagemans; Lodewijk IJlst; Ronald J A Wanders; Frits A Wijburg; Naomi van Vlies
Journal:  Orphanet J Rare Dis       Date:  2013-07-09       Impact factor: 4.123

2.  Assessment of dysmyelination with RAFFn MRI: application to murine MPS I.

Authors:  David Satzer; Christina DiBartolomeo; Michael M Ritchie; Christine Storino; Timo Liimatainen; Hanne Hakkarainen; Djaudat Idiyatullin; Silvia Mangia; Shalom Michaeli; Ann M Parr; Walter C Low
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.